The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- Track and Trace Guidance Outlines Ways to Exchange Data; Guidance on Standardization and Documentation Still to Come Nov. 26, 2014
- Epidural Steroid Injection Advisory Committee Leaves FDA with Flexibility on Contraindications Nov. 25, 2014
- FDA NME “Snapshots” Provide Short-Form Access to FDA Detailed Drug Approval Data and Demographic Profile Nov. 25, 2014
See More Research Notes